Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy
Engineering nanoparticles with optimal properties for use in cancer therapies.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 48-52

References

1. M. Morgen et al., Pharm. Res. 29 (2) 427-440 (2012).

2. A. Siew et al., Mol. Pharm. 9 (1) 14-28 (2012).

3. C. Liu et al., Biomat. 34 (10) 2547-2564 (2013).

4. I. Altintas et al., J. Control. Rel. 165 (2) 110-118 (2013).

5. W.Y. Qian et al., Int. J. Nanomed. 7: 5781-5792 (2012).

6. J.H. Sung, D. Han, and J.B. Lee, Biotechnol. J. 8 (2) 215-220 (2013).

7. C.Y. Dombu and D. Betbeder, Biomat. 34 (2) 516-525 (2013).

8. S. Hauptstein and A. Bernkop-Schnurch, Expert. Opin. Drug Deliv. 9 (9) 1069-1081 (2012).

9. R. Singh and J.W. Lillard, Exp. Mol. Pathol. 86 (3) 215-223 (2009).

10. A.Z. Wang, R. Langer, and O.C. Farokhzad, Annu. Rev. Med. 63: 185-198 (2012).

11. A. Swami et al., "Nanoparticles for targeted and temporally controlled drug delivery," in Multifunctional Nanoparticles for Drug Delivery Applications, S. Svenson and R.K. Prud'homme, Eds. (Springer, US, 2012), pp. 9-29.

12. NanoCarrier, "NC-6004 Nanoplatin," http://www.nanocarrier.co.jp/en/research/pipeline accessed Feb. 8, 2013.

13. H. Uchino et al., Br. J. Cancer 93 (6) 678-687 (2005).

14. R. Plummer et al., Br. J. Cancer 104 (4) 593-598 (2011).

15. Cerulean, "CRLX101," http://ceruleanrx.com/, accessed Feb. 8, 2013.

16. Young et al., Curr. Bioact. Compd. 7 (1) 8-14 (2011).

17. T. Hamaguchi et al., Br. J. Cancer 92 (7) 1240-1246 (2005).

18. Zhang et al., Adv. Funct. Mat. 22 (24) 5144-5156 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here